Skip to main content
SpringerLink
Log in

Pharmacotherapy of Lupus Nephritis in Children

A Recommended Treatment Approach

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease of unknown aetiology, which is characterised by recurrent disease flares that may affect any organ system. Renal involvement remains one of the chief causes of morbidity and mortality in children with lupus. Nephritis occurs in approximately two-thirds of patients, ranging from mild glomerulitis to life-threatening occurrences of diffuse proliferative glomerulonephritis. As lupus nephritis is a condition of no single aetiology, there is no single cure. Corticosteroids, although still the first line of treatment, are increasingly being superseded by cytotoxic drugs, in particular cyclophosphamide and corticosteroid-sparing agents. Newer agents such as mycophenolate mofetil, although effective in the treatment of lupus in adults, are less effective in children. Standard of care for highly active lupus nephritis in children remains intravenous cyclophosphamide, although preliminary experience suggests that the addition of rituximab may allow for remission induction with a reduction in cumulative cyclophosphamide dose. Combination therapies and newer agents appear promising for the future as our understanding of the immune system and its dysregulation in SLE improves. In this review, we discuss the current standards of care, newer therapies currently in use, and emerging treatments still undergoing development and investigation. We conclude by discussing our guidelines for treatment at the present time and suggestions for the comprehensive care of children with lupus nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 4th ed. Philadelphia (PA): WB Saunders Company, 2001

    Google Scholar 

  2. Hochberg M. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977. Arthritis Rheum 1985; 28: 80–6

    Article  PubMed  CAS  Google Scholar 

  3. Siegel M, Lee ML. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 1973; 3: 1–54

    Article  PubMed  CAS  Google Scholar 

  4. Lehman TJA, McCurdy DK, Bernstein BH, et al. Systemic lupus in the first decade of life. Pediatrics 1989 Feb; 83(2): 235–9

    PubMed  CAS  Google Scholar 

  5. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol 1994; 8: 230–49

    Article  PubMed  CAS  Google Scholar 

  6. McCurdy DK, Lehman TJ, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992; 89(2): 240–6

    PubMed  CAS  Google Scholar 

  7. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002 Dec; 29(12): 2635–42

    PubMed  Google Scholar 

  8. Spahn JD, Kamada AK. Special considerations in the use of glucocorticoids in children. Pediatr Rev 1995; 16: 266–72

    Article  PubMed  CAS  Google Scholar 

  9. Satel SL. Mental status changes in children receiving glucocorticoids. Clin Pediatr (Phila) 1990; 29: 382–8

    Article  Google Scholar 

  10. Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113: 249–54

    Article  PubMed  CAS  Google Scholar 

  11. Loeb JN. Corticosteroids and growth. N Engl J Med 1976; 295: 547–52

    Article  PubMed  CAS  Google Scholar 

  12. McCarthy TL, Centrella M, Canalis E. Cortisol inhibits the synthesis of insulin-like growth factor 1 in skeletal cells. Endocrinology 1990; 126: 1569–75

    Article  PubMed  CAS  Google Scholar 

  13. Lehman TJA, Mouradian JA. Systemic lupus erythematosus. In: Holliday M, Barratt M, Avner ED, editors. Pediatric nephrology. 4th ed. Baltimore (MD): William and Wilkins, 1999

    Google Scholar 

  14. Ilowite NT, Samuel P, Ginzler E, et al. Dyslipoprotienemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988 Jul; 31(7): 859–63

    Article  PubMed  CAS  Google Scholar 

  15. Ilowite NT. Premature Atherosclerosis in systemic lupus erythematosus. J Rheumatol Suppl 2000 Apr; 58: 15–9

    PubMed  CAS  Google Scholar 

  16. Barron KS, Person DA, Brewer EJ, et al. Pulse methylprednisolne therapy in diffuse proliferative lupus nephritis. J Pediatr 1982 Jul; 101(1): 137–41

    Article  PubMed  CAS  Google Scholar 

  17. Garin EH, Sleasman JW, Richard GA, et al. Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. Eur J Pediatr 1986 Oct; 145(5): 380–3

    Article  PubMed  CAS  Google Scholar 

  18. Lehman TJ, Sherry DD, Wagner-Weiner L, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989 Jun; 114(6): 1055–60

    Article  PubMed  CAS  Google Scholar 

  19. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000 Feb; 136(2): 243–7

    Article  PubMed  CAS  Google Scholar 

  20. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004; 63: 321–3

    Article  PubMed  CAS  Google Scholar 

  21. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003 Jun; 48(6): 1484–92

    Article  PubMed  CAS  Google Scholar 

  22. Looney RJ, Anolik JH, Campbell D, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose escalation trial of Rituximab. Arthritis Rheum 2004 Aug; 50(8): 2580–9

    Article  PubMed  CAS  Google Scholar 

  23. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down regulation of the T-cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005; 52(2): 501–13

    Article  PubMed  CAS  Google Scholar 

  24. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550–7

    Article  PubMed  CAS  Google Scholar 

  25. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus ertheymatosus. Arthrtis Rheum 2004; 50(11): 3580–90

    Article  CAS  Google Scholar 

  26. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52(10): 3168–74

    Article  PubMed  CAS  Google Scholar 

  27. McCune WJ, Riskalla MM. Mycophenolate mofetil: a magic bullet for lupus? J Rheum 2005 Jun; 32(6): 1047–52

    Google Scholar 

  28. Kimball JA, Pescovitz MD, Book BK, et al. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995 Dec; 60(2): 1379–83

    Article  PubMed  CAS  Google Scholar 

  29. Raab M, Daxecker H, Pavlovic V, et al. Quantification of the influence of mycophenolic acid on the release of endothelial adhesion molecules. Clin Chim Acta 2002 Jun; 320(1–2): 89–4

    Article  PubMed  CAS  Google Scholar 

  30. Lui SL, Tsang R, Wong D, et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11(7): 411–8

    Article  PubMed  CAS  Google Scholar 

  31. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004 Jun; 77(11): 1661–7

    Article  PubMed  CAS  Google Scholar 

  32. Ginzler EMAC, Buyon J, Dooley MA, et al. A multicenter study of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN); preliminary results [abstract]. Arthritis Rheum 2003; 48 Suppl.: S647

    Google Scholar 

  33. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705–9

    CAS  Google Scholar 

  34. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–80

    Article  PubMed  CAS  Google Scholar 

  35. Fu YF, Lu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001 Apr; 55(4): 318–21

    PubMed  CAS  Google Scholar 

  36. Buratti S, Szer S, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001 Sep; 28(9): 2103–8

    PubMed  CAS  Google Scholar 

  37. Fu LW, Yang LY, Chan WP, et al. Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephrtitis with heavy proteinuria. Br J Rheumatol 1998; 37: 217–21

    Article  PubMed  CAS  Google Scholar 

  38. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969–74

    Article  PubMed  CAS  Google Scholar 

  39. Kalunian KC, Davis JC, Merrill JT, et al. IDEC-131 Lupus study group. Treatment of systemic lupus erythematosus by inhibition of T cell co-stimulation with antiCD154: a randomised double-blind, placebo controlled trial. Arthritis Rheum 2002; 46: 3251–8

    CAS  Google Scholar 

  40. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40-ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719–27

    Article  PubMed  CAS  Google Scholar 

  41. Finck B, Linsley P, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225–7

    Article  PubMed  CAS  Google Scholar 

  42. Hervey PS, Keam SJ. Abatacept. BioDrugs 2006; 20(1): 53–62

    Article  PubMed  CAS  Google Scholar 

  43. Tahir H, Isenberg DA. Novel therapies in lupus nephritis. Lupus 2005; 14: 77–82

    Article  PubMed  CAS  Google Scholar 

  44. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005; 14: 189–91

    Article  PubMed  CAS  Google Scholar 

  45. Stohl W. A therapeutic role for BLys. Lupus 2004; 13: 317–22

    Article  PubMed  CAS  Google Scholar 

  46. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLys (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002; 14: 522–8

    Article  PubMed  CAS  Google Scholar 

  47. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003 Jan; 48(1): 166–7322

    Article  PubMed  CAS  Google Scholar 

  48. Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol 2003; 16: 787–91

    PubMed  Google Scholar 

  49. Stone JH, Millward CL, Olson JL, et al. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998; 41: 678–86

    Article  PubMed  CAS  Google Scholar 

  50. Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75: 651–6

    Article  PubMed  Google Scholar 

  51. Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005; 14: 95–8

    Article  PubMed  CAS  Google Scholar 

  52. Ilei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248–57

    Google Scholar 

  53. Rudge S, Hailwood S, Home A, et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology 2005; 44: 813–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Division of Pediatric Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, New York, 10021, USA

    Alexa Adams, Emma Jane MacDermott &  Thomas J. A. Lehman

  2. Department of Pediatrics, Weill Cornell Medical Center, New York, USA

    Thomas J. A. Lehman

Authors
  1. Alexa Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma Jane MacDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas J. A. Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. A. Lehman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, A., MacDermott, E.J. & Lehman, T.J.A. Pharmacotherapy of Lupus Nephritis in Children. Drugs 66, 1191–1207 (2006). https://doi.org/10.2165/00003495-200666090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666090-00003

Keywords

Search

Navigation